

The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells

Supplementary Material




Fig S1: PRIMA-1 does not influence VMY sensitivity in **A)** p53 WT and **B)** p53 null prostate cancer cells. Both cell types were treated with 75 uM PRIMA-1 and either VMY at 10uM or 30uM or 30 uM PVB (purvalanol B) at 30uM for 18 hrs. Cell viability was measured by trypan blue dye exclusion.




Fig S2: VMY fails to induce autophagy in PC3 (Left) and DU145 cells (Right) as measured by LC3-GFP fluorescence. 3MA, 3-methyladenine






Fig S3: Basal levels of autophagic proteins in DMSO control cells. The effects of 5 μ M 3-methyladenine(3-MA) or 50 μ M chloroquine (CQ) on the autophagic markers p62 and LC3I/II, were assessed in LNCaP cells. Samples were collected at the times shown. The membranes were probed for p62 and LC3I/II, with β -actin as a loading control.




B
Patient 1: Tumor Derived CRCs



	Treatment	
(%)	DMSO	VMY (30uM)
G1	86	67
S	10	20
G2/M	4	13
subG1	9	20
annexin V	1.6	5.7

Patient 2: Tumor Derived CRCs



	Treatment	
(%)	DMSO	VMY (30uM)
G1	82	82
S	8	15
G2/M	10	3
subG1	3	10
annexin V	2.0	4.4

Fig S4: Effects of VMY on CRCs from Patients 1 and 2. **A)** Cell viability as measured by trypan blue of patient-matched CRCs following 18hr exposure to 30uM VMY. **B)** Cell cycle effect of 18hr exposure to 30uM VMY as measured by flow cytometry. * $p < 0.05$.

CRCs from Patient 2

